ArQule Reports Results From Ongoing Phase 1 Dose Escalation Study Of ARQ 531, Showed 'preliminary anti-tumor activity at all dose levels, resulting in an observed tumor reduction of 35% at 5mg, 33% at 10mg, and 29% at 15mg doses'